Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Increases speed to market for drug developers working on nucleic acid therapeutics.

The global proteinase K market is projected to grow from US$ 27.5 million in 2023 to US$ 43.9 million by 2033, at a CAGR of 4 ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Human Metapneumovirus (HMPV) primarily spreads through respiratory secretions from coughing or sneezing, close personal ...

Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...